Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Heart involvement in systemic sclerosis].

Yannick Allanore1, André Kahan

  • 1Université René Descartes, Faculté de Médicine, Service de Rhumatologie A, Hôpital Cochin, AP-HP, Paris. yannick.allanore@cch.aphp.fr

Presse Medicale (Paris, France : 1983)
|December 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.

Journal of scleroderma and related disorders·2022
Same author

Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers.

Journal of scleroderma and related disorders·2022
Same author

Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection.

Rheumatology (Oxford, England)·2022
Same author

Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort.

Rheumatology (Oxford, England)·2022
Same author

Driving Role of Interleukin-2-Related Regulatory CD4+ T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2022
Same author

Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment.

Rheumatology (Oxford, England)·2022
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Systemic sclerosis commonly affects the heart, leading to myocardial fibrosis via microcirculatory impairment. Early treatment with calcium channel blockers and ACE inhibitors is crucial for managing cardiac involvement in systemic sclerosis.

Area of Science:

  • Cardiology
  • Rheumatology
  • Vascular Biology

Background:

  • Primary myocardial involvement is frequent in systemic sclerosis.
  • Cardiac involvement, particularly myocardial fibrosis from ischemic injury, is a poor prognostic indicator.
  • Microcirculatory impairment and abnormal vasoreactivity are implicated in the pathogenesis of cardiac dysfunction.

Purpose of the Study:

  • To elucidate the mechanisms of cardiac involvement in systemic sclerosis.
  • To highlight the prognostic significance of cardiac manifestations.
  • To review current treatment strategies for myocardial involvement.

Main Methods:

  • Review of existing evidence on cardiac involvement in systemic sclerosis.
  • Analysis of pathological mechanisms including microcirculatory impairment and fibrosis.

Related Experiment Videos

  • Evaluation of clinical outcomes and treatment efficacy.

    • Main Results:

    • Myocardial fibrosis due to repeated focal ischemic injury is a key feature.
    • Pericardial and conduction system abnormalities are common but often asymptomatic or non-serious.
    • Arrhythmias can be life-threatening, while valvular involvement is minimal.
    • Calcium channel blockers and ACE inhibitors are primary treatment modalities.

    Conclusions:

    • Cardiac involvement in systemic sclerosis, primarily myocardial fibrosis, significantly impacts prognosis.
    • Management requires addressing microcirculatory dysfunction and utilizing specific pharmacotherapies.
    • Long-term treatment with vasodilators is essential for patients with systemic sclerosis and cardiac involvement.